AI are (going to be) people too

BY KIM BELLARD

My heart says I should write about Uvalde, but my head says, not yet; there are others more able to do that.  I’ll reserve my sorrow, my outrage, and any hopes I still have for the next election cycle.  

Instead, I’m turning to a topic that has long fascinated me: when and how are we going to recognize when artificial intelligence (AI) becomes, if not human, then a “person”?  Maybe even a doctor.

What prompted me to revisit this question was an article in Nature by Alexandra George and Toby Walsh:Artificial intelligence is breaking patent lawTheir main point is that patent law requires the inventor to be “human,” and that concept is quickly become outdated.   

It turns out that there is a test case about this issue which has been winding its way through the patent and judicial systems around the world.  In 2018, Stephen Thaler, PhD, CEO of Imagination Engines, started trying to patent some inventions “invented” by an AI system called DABUS (Device for the Autonomous Bootstrapping of Unified Sentience).  His legal team submitted patent applications in multiple countries.

It has not gone well.  The article notes: “Patent registration offices have so far rejected the applications in the United Kingdom, United States, Europe (in both the European Patent Office and Germany), South Korea, Taiwan, New Zealand and Australia…But at this point, the tide of judicial opinion is running almost entirely against recognizing AI systems as inventors for patent purposes.”  

The only “victories” have been limited.  Germany offered to issue a patent if Dr. Thaler was listed as the inventor of DABUS.  An appeals court in Australia agreed AI could be an inventor, but that decision was subsequently overturned.  That court felt that the intent of Australia’s Patent Act was to reward human ingenuity. 

The problem is, of course, is that AI is only going to get more intelligent, and will increasingly “invent” more things.  Laws written to protect inventors like Eli Whitney or Thomas Edison are not going to work well in the 21st century. The authors argue:

In the absence of clear laws setting out how to assess AI-generated inventions, patent registries and judges currently have to interpret and apply existing law as best they can. This is far from ideal. It would be better for governments to create legislation explicitly tailored to AI inventiveness.

Those aren’t the only issues that need to be reconsidered.  Professor George notes:

Even if we do accept that an AI system is the true inventor, the first big problem is ownership. How do you work out who the owner is? An owner needs to be a legal person, and an AI is not recognized as a legal person,

Another problem with ownership when it comes to AI-conceived inventions, is even if you could transfer ownership from the AI inventor to a person: is it the original software writer of the AI? Is it a person who has bought the AI and trained it for their own purposes? Or is it the people whose copyrighted material has been fed into the AI to give it all that information?

Yet another issue is that patent law typically requires that patents be “non-obvious” to a “person skilled in the art.”  The authors point out: “But if AIs become more knowledgeable and skilled than all people in a field, it is unclear how a human patent examiner could assess whether an AI’s invention was obvious.”  

————–

I think of this issue particularly due to a new study, where MIT and Harvard researchers developed an AI that could recognize patients’ race by looking only at imaging.  Those researchers noted: “This finding is striking as this task is generally not understood to be possible for human experts.”  One of the co-authors told The Boston Globe: “When my graduate students showed me some of the results that were in this paper, I actually thought it must be a mistake. I honestly thought my students were crazy when they told me.”

Explaining what an AI did, or how it did it, may simply be or become beyond our ability to understand.  This is the infamous “black box” issue, which has implications not only for patents but also liability, not to mention teaching or reproducibility.  We could choose to only use the results we understand, but that seems pretty unlikely.  

Professors George and Walsh propose three steps for the patent problem:

  • Listen and Learn: Governments and applicable agencies must undertake systematic investigations of the issues, which “must go back to basics and assess whether protecting AI-generated inventions as IP incentivizes the production of useful inventions for society, as it does for other patentable goods.”
  • AI-IP Law: Tinkering with existing laws won’t suffice; we need “to design a bespoke form of IP known as a sui generis law.”
  • International Treaty: “We think that an international treaty is essential for AI-generated inventions, too. It would set out uniform principles to protect AI-generated inventions in multiple jurisdictions.”  

The authors conclude: “Creating bespoke law and an international treaty will not be easy, but not creating them will be worse. AI is changing the way that science is done and inventions are made. We need fit-for-purpose IP law to ensure it serves the public good.”

It is worth noting that China, which aspires to become the world leader in AI, is moving fast on recognizing AI-related inventions.  

————

Some experts posit that AI is and always will be simply a tool; we’re still in control, we can choose when and how to use it.  It’s clear that it can, indeed, be a powerful tool, with applications in almost every field, but maintaining that it will only ever just be a tool seems like wishful thinking.  We may still be at the stage when we’re supplying the datasets and the initial algorithms, and even usually understanding the results, but that stage is transitory.  

AI are inventors, just like AI are now artists, and soon will be doctors, lawyers, and engineers, among other professions.  We don’t have the right patent law for them to be inventors, nor do we have the right licensing or liability frameworks for them to in professions like medicine or law.  Do we think a medical AI is really going to go to medical school or be licensed/overseen by a state medical board?  How very 1910 of us!

Just because AI aren’t going to be human doesn’t mean they aren’t going to be doing things only humans once did, nor that we shouldn’t be figuring out how to treat them as persons.   

Kim is a former emarketing exec at a major Blues plan, editor of the late & lamented Tincture.io, and now regular THCB contributor.

from The Health Care Blog https://ift.tt/YHGIP4e

A deal on AHIP in Vegas!

I’m going to AHIP in Vegas next month and you should come too!

It’s time to be together again. It’s also time to save. Register for AHIP 2022 (formerly Institute & Expo), June 21 – 23 in Las Vegas with code THCB and save. Together, we’ll explore the ideas, innovations, and forward-thinking driving health care’s transformation. Check out the agenda and Register today with code THCB.

from The Health Care Blog https://ift.tt/gbKA8qe

The Mental Health ‘Formulary of the Future’? Otsuka’s Work in DTx, Psychedelics, & More

By JESSICA DaMASSA, WTF HEALTH

Otsuka Pharmaceuticals is expanding its mental health formulary – looking beyond traditional medications to psychedelics, and to the “intersection of technology and psychiatry” with digital therapeutics currently in clinical trials for Major Depressive Disorder. Kabir Nath, Senior Managing Director of Otsuka’s Global Pharmaceutical Business, lets us in on the thinking behind these bold moves, why the pharma co is even innovating to expand the spectrum of treatments available for mental illness in the first place, and how soon these new therapies will reach patients.

“Follow the science” is a key undercurrent of this conversation, particularly as we talk through Otsuka’s investments in psychedelic medicine start-ups Compass Pathways and, more recently, Mindset. Kabir says the body of clinical evidence for these therapies is building and we get his prediction on when they might become more mainstream and readily available.

We also get his take on digital therapeutics (DTx) and the work Otsuka is doing with Click Therapeutics in Major Depressive Disorder. Their clinical trial, done in partnership with Verily, is the first-ever fully remote clinical trial conducted in this space, and the hope is that it not only generates evidence to support the emerging DTx category, but that it also sets a precedent for a new, tech-enabled way to run clinical trials.

This is just the beginning. There’s lots more on the innovations changing pharma and the future of mental health care in this one. Watch now!

from The Health Care Blog https://ift.tt/XHWgwfS

British Doctor Suspended for falsely claiming she was “promised” a laptop. WTF!

BY SAURABH JHA

If forced to choose Britain’s two biggest contributions to civilizations, I’d pick the Magna Carta and the vaguely instructional “fuck off.” If permitted a third, I’d choose “managerialism.” Brits are good at telling others what to do. Managerialism is how the Brits once ruled India. Buoyed by the colonial experience, British managers felt they could rule doctors. 

The new Viceroy, the manager-in-chief, is the General Medical Council (GMC). The GMC is a physician watchdog, funded by doctors, which works for the public good and is answerable to…well, I’ll get to that later. Their relevance rose exponentially when the psychopathic Dr. Harold Shipman, a charming, clinically adept, general practitioner, killed over two hundred patients. Never again, said the managers. They promised to keep the public safe from dodgy doctors with aspirations of Jack the Ripper and Sweeney Todd.

Recently, Dr. Manjula Arora, a doctor of Indian origin, was in GMC’s crossfire. Though I don’t know Dr. Arora personally, I’d hazard a guess that she didn’t migrate to the UK to emulate Harold Shipman. It’s also unlikely, and this may surprise some, that she left India for fortune and glory – doctors in India do well fiscally when you factor in the living costs. She may have been motivated by greener educational pastures in the UK, the sort that produces managers and doctors. 

How did the GMC save the vulnerable British public from the “dangerous” Dr. Arora? Her story is part tragic and part comical, and both comedy and tragedy jostle for the upper hand. One evening Dr. Arora asked her healthcare (Mastercall) Information Technology (IT) for a laptop. She said that she had been promised a laptop by the medical director. The IT department e-mailed her medical director (MD) and asked whether she had truly been promised a laptop.

The MD balked at the insinuation that he had broken his promise to Dr. Arora since at no point had he used the “p” word. At this stage let’s reflect on the gravity of the charge. Any parent knows that you never say the “p” word to your kids. I have threatened my kids with mythical monsters when they falsely accuse me of promising. Once, I confiscated their ice cream for accusing me of breaking my promise. The medical director reported Dr. Arora to the GMC for falsely accusing him of using the “p” word. 

The GMC, far from mythical, considered whether Dr. Arora, a first-class doctor with thirty years of experience, was an imminent threat to the public for lying that she had been promised a laptop. For who knows what a doctor who lies about the “p” word can do next? She might administer potassium to her patients and go on a killing rampage. 

The GMC has its own court in which it prosecutes dodgy doctors – the Medical Practitioners Tribunal Service (MPTS), or tribunal. Allegedly independent of the GMC, MPTS is supposed to be GMC’s wise Solomon, dispensing justice disinterestedly on facts and precedence. Busy people assembled displaying their finest lapels and imbibing the wisdom of the Magna Carta decided whether Dr. Arora was fit to be a doctor. On trial weren’t Dr. Arora’s clinical skills, or patient-centeredness, or whether Dr. Arora could manage an acute abdomen. On trial was her understanding of the word “promise.” It was a trial of semantics. Did she lie that the medical director had promised her a laptop? 

It turns out that the medical director hadn’t promised Dr. Arora a laptop. He said she may get one in the next round of purchases. Since “may” comes with “may not,” Dr. Arora was literally wrong that he had “promised” her a laptop. 

The “Promise”

This is what the medical director emailed Dr. Arora. (Emphasis mine) 

“We don’t have any laptops at present, but I will note your interest when the next rollout happens. Technology is advancing, we may soon be able to allow clinicians to use their own computers, watch this space.” 

The “Lie”

This is what Dr. Arora told IT. The medical director is referred to as “Dr. B” in the MPTS’s transcript. The MPTS doesn’t disclose the name of the accusers, only the accused. (Emphasis mine)

“Oh right, because he [Dr B] didn’t have a laptop and he sent me an email that the next time it’s available he’ll give it to me, so you have laptops and I thought it’s best that I take one because I don’t want too many people to be involved, just him and you directly, because it’s my … it’s [Dr B] who has promised it.”

The Trial of Semantics

The tribunal wondered whether Dr. Arora truly understood what “promise” means. Dr. Arora said since English isn’t her first language she doesn’t always get the semantics 100 % accurate. The GMC disagreed and said Dr. Arora was in fact very articulate and had a good command of the language, noting she was “very easily able to answer questions in cross-examination,” that she was “able to formulate arguments very well,” that she could “adapt her evidence as she went along,” that she was “able to anticipate questions.”

Dr. Arora was asked whether the medical director had promised her the laptop, yes or no. She replied, “It’s the connotation that I had taken from it.” 

Then Mr. Carl Hargan, representing the GMC, with all his intellectual might, asked her a question which’d make schoolmarms proud. He asked if there was a “huge leap” between the phrase “note your interest” and a promise. Dr. Arora had no answer. She was stumped by Mr. Hargan’s brilliance. As was the MPTS.

The Verdict

The tribunal agreed with the GMC that Dr. Arora understood the meaning of the word “promise.” The Tribunal, “determined that, in the specific use of that one word, on that one occasion, she had been dishonest.” Which meant that she lied. 

Now, the tribunal had to decide if Dr. Arora was fit to practice medicine. So, it went through case law and sought the Shipman Report. Remember Shipman? Yes, that serial killer. That report states that “dishonesty” is a reason to question a doctor’s fitness to practice. For this “lie,” technically an exaggeration, the tribunal found Dr. Arora unfit to practice and suspended her for one month. 

Kafka meets Edmund Blackadder

Let’s pause and take a deep breath. Britain is a country where the Prime Minister can lie about partying in a lockdown he instituted, but an overworked doctor gets punished because she misuses “promise.” 

At this stage American readers are probably seething in incredulity – what the fuck? You ask. Even if she lied, so what? You may believe that I’m making stuff up. No, this isn’t a Monty Python script. This isn’t Dolores Umbridge holding a kangaroo court in Hogwarts School of Magic. This is the judgment of the tribunal of the watch dog of the most prestigious profession in a once upon a time super power – the one you expelled on the 4th of July. 

I’ll leave the irony that in a country which gave us Shakespeare, who gave us boundless metaphorical permutations, we have a trial about semantics! I have noticed on Twitter that Brits are increasingly becoming more literal and a tad dafter, as a result. Brits are better off staying metaphorical. But even allowing for these comical secular trends, the trial of Dr. Arora takes stupidity in the British medical profession to a level one struggles to comprehend. 

From protecting patients from murderous doctors, the GMC has gone to protecting the Oxford English Dictionary from brown doctors. The GMC is the best example of the slippery slope. The British public may wonder why the watch dog which was supposed to protect them from bad doctors has deprived them of a good doctor, just when there’s severe staffing shortage in the NHS, and even severer shortage of physician morale, post pandemic. 

There are three breaches of common sense and basic adult behavior. First, the medical director reported Dr. Arora to the GMC for, at worst, an exaggerated interpretation of his generosity. This could have been resolved locally with a stern “no, I didn’t promise.” He could even have confiscated her ice cream. Second, the GMC, instead of throwing the complaint back at the medical director with the scorn it deserved, thought the charge fit to investigate the doctor’s fitness to practice. And third the guilty verdict passed by the MPTS, after an intense academic deliberation. A true Mad Hatter party! 

Why wasn’t the issue left between employer and employee? My guess is that the medical director couldn’t remove Dr. Arora because she’s a good doctor. The only way of punishing competent doctors in Britain is going  after their moral character and reporting them to the GMC.

Why has the GMC become so farcical? One explanation is that the GMC is racist and the treatment meted to Dr. Arora is just another example of systemic racism. There’s certainly merit here but there’s a deeper problem which needs solving and that is the GMC isn’t accountable to anyone. In theory, it works for society, but as Margaret Thatcher correctly understood, there’s no such thing as society. It’s a nebulous entity that’s thrown around but means nothing. Being accountable to the public means being accountable to no one. 

The irony is that the medical director sent Dr. Arora the email “promising” her a laptop on Christmas Eve. It’s the time of the year when even the loathsome Scrooge lightened up. What then emboldened the medical director to be a tattletale? What motivated him to try to destroy Dr. Arora’s career and her family of an income source? Why so much hate in his bosom for his colleague? 

The tempting answer is that he’s a prick of the sort that takes years of mastery. But that doesn’t explain. To understand the medical director’s behavior, we must understand the GMC because the two are linked, causally. The GMC’s power has become absolute both by design and intention. The GMC hides under the carapace of “protecting the patient,” and in this dumbed down, sentimental medical world, nothing is more sacrosanct than the dull truism “it’s about the patient,” a truism so banal that it serves little purpose other than providing assholes moral sanctuary. 

But even here the GMC falls short. How can it claim to be protecting patients when it deprives patients of competent doctors? Instead of treating patients, Dr. Arora was defending her over use of the metaphorical license, thanks to her boss and the GMC. 

The GMC is not only a farce and bully in its own right, but also encourages bullying – this is a feature not a bug. It’s like bellows to ember. It flames toxicity in the workplace. It nurtures vindictiveness and pettiness in the NHS, like agar to bacteria. This is the only example I know of in the modern world of trickle-down vileness. The threat of reporting to the GMC is how the clinical directors control their minions. It’s not about patient safety, it never was. It’s about the power of managers and their control over doctors. 

Mr. Hargan said that Dr Arora had ‘brought the medical profession into disrepute,’ ‘breached a fundamental tenet of the profession,’ and that ‘her integrity could not be relied upon.’ Mr. Hargan said that “that a finding of impairment was necessary in order to maintain public confidence in the profession.”

Let’s unpack this. The other role of the GMC is to protect the reputation of the medical profession. And doctors with unconventional extracurricular interests can certainly damage the reputation of the profession. But if Bashar-Al-Assad, a former ophthalmologist and current Syrian president with a fondness for chemical reactions, doesn’t make people wonder if their ophthalmologists were going to spray tear gas once they dilated their pupils, I’m fairly certain Dr. Arora’s patients won’t second guess her prescriptions because she mistook “watch this space” for “I promise you a laptop.”

Mercifully, even the MPTS accepted “Dr Arora had not set out to be dishonest, and that she had not set out to mislead.” There’s dishonesty – lying about killing your patients (Harold Shipman) and there’s dishonesty – lying about being promised a laptop (Manjula Arora). Are British regulatory agencies too thick to make this distinction, or does this distinction not matter?

Society is better off when the likes of Mr. Hargan are grading high school essays than deciding physician misconduct. I’m certain Mr. Hargan is far too clever to believe his own nonsense. So why does he think doctors will believe his BS? Where does he get the audacity for such contempt of doctors’ intelligence?

To put it bluntly. The GMC doesn’t give a rat’s tail what doctors think. And why should they? All they care is that doctors give them their annual check, which doctors do, religiously. 

What’s the solution? 

Hand wringing and whining, at which doctors excel, won’t work. Despite the outrage, doctors couldn’t reform the GMC when the GMC sued the MPTS, its own judiciary, because it handed Dr. Bawa-Garba her license after her sentence. British doctors need to borrow a slice of timeless American wisdom – follow the money. Americans long realized that logos, ethos, and pathos don’t work with our species. If you want institutions to behave, fund them to behave, and if you don’t like how they behave, defund them. Money, or the threat of losing it, can reform the GMC in minutes. Appeals to their better angels will take eternity. 

Doctors should form a watch dog, run by practicing doctors, which monitors and holds accountable the GMC and MPTS – a meta-tribunal of sorts. If the GMC refuses to submit its decisions to an external agency, doctors shouldn’t pay their dues. Of course, this won’t be easy. Of course, it’ll need organized leadership. And of course, some doctors will opt out of collective resistance because it doesn’t affect them. But it’s the only solution. It’s the only way to tame the GMC. The GMC is a threat to the morale of doctors. The GMC isn’t fit to practice. Reform it or create an alternative. 

@RogueRad is a former NHS doctor

The transcript of the entire circus can be found here

from The Health Care Blog https://ift.tt/FhgJTCX

THCB Gang Episode 93, Thursday May 26 1pm PT, 4pm ET

Joining Matthew Holt (@boltyboy) on #THCBGang on Thursday May 26 are medical historian Mike Magee (@drmikemagee); Suntra Modern Recovery CEO JL Neptune (@JeanLucNeptune); and be fierce patient activist Casey Quinlan (@MightyCasey). you can imagine we’ll be talking about data, and sadly guns as a public health crisis.

You can see the video below live (and later archived) & if you’d rather listen than watch, the audio is preserved as a weekly podcast available on our iTunes & Spotify channels.

from The Health Care Blog https://ift.tt/RQtT4a9

#HealthTechDeals Episode 31| Homethrive, Greater Good, Parallel Learning, Cayaba Care, Miga Health

You know what Jess just realized? We haven’t heard my opinion on Cerebral! Scandal! Firings! Intrigue! Legal Issues! Risk! Skyrocketing! Dying! Cerebral offers quite some food for thought. Check out the episode for my opinion on this incredibly fast-brewing story as well as more multi-million deals: Homethrive raises $20 million; Greater Good raises $10 million; Parallel Learning raises $20 million; Cayaba Care raises $12 million; Miga Health raises $12 million.

-Matthew Holt

from The Health Care Blog https://ift.tt/1Bp3svI

Defanging HIPAA: How Your De-identified Data Was Re-identified For Profit.

BY MIKE MAGEE, M.D.

Arthur Sackler continues to demonstrate just how wealthy one can become by advantaging patients and their diseases.

He’s been dead since 1987, but his ghost continues to access your personal health data, pushes medical consumption and over-utilization, and expands profits exponentially for data abusers well beyond his wildest dreams. Back in 1954, he and his friend and secret business partner, Bill Frohlich, were the first to realize that individual health data could be a goldmine. That relationship would still be a secret had it not been exposed in a messy family inheritance feud unleashed by his third wife after Sackler’s death.

That company, IMS Health, was taken public and listed on the NYSE on April 4, 2014, transferring $1.3 billion in stock. I’ll come back to that in a moment. But in the early years, the pair realized that the data they were collecting would multiply in value if it could be correlated with a second data set. That dataset was the AMA’s Physician Masterfile which tracked the identity and location of all physicians in America from the time they entered medical school. 

Those doctors were largely unaware that they had been assigned an identifier number early in their career, or that they were being tracked, or that the AMA was profiting from the sales of their information. With this additional information, IMS information products helped inform companies’ commercialization plans, their pharmaceutical marketing and sales, and eventually the targeting of physicians most likely to overprescribe Oxycontin.

After Arthur Sackler’s death, the company was sliced and diced, sold and resold, merged and divested. In May 2016, IMS merged with Quintiles with ownership at 51.4% IMS and 48.6% Quintiles. The resulting company was valued at  $17.6 billion and called QuintilesIMS. On November 6, 2017, it was renamed IQVIA. 

Two decades earlier,  Congress had passed HIPAA , designed to protect patients’ personal health information, but leaving health care organizations (not patients) in control of that data. In a compromise, those organizations were permitted to sell and mine aggregate data as long as it was detached from personal identifiers such as names, birthdates, and ZIP codes.

Under the mantra of “de-identification,” the Medical-Industrial Complex went to work. One of the most successful of the lot was a West Coast start-up, MedicaLogic, which created a shared patient case database fed by thousands of doctors nationwide.  The doctors were assured that the data housed in their proprietary medical record system was de-identified and intended for altruistic purposes. But its commercial worth quickly became evident resulting in a sale to GE Health in 2002, becoming their “must-have” MQIC database

By 2013, it had been six-figure licensed to over 500 corporate clients and included focused marketing and sales insights from data mining the records of 25 million de-identified Americans over a 15 year span. Its premier customer was QuintilesIMS, now generating $4 billion in annual revenue, employing 33,000 employees and running the clinical research (largely overseas) operations for 20 of the largest pharmaceutical companies.

QuintilesIMS, now IQVIA, was the owner of MarketScan, the domicile for a 270 million Americans-strong health insurance claims repository. The original creator of MarketScan was Truven Health Analytics. IQVIA took the data from GE’s MQIC database and merged it with Truven’s MarketScan with an aim of re-identifying your health data, thus vastly expanding its commercial value. The results were alarming. As an internal GE memo later revealed, the cross-reference with Tureen data allowed re-identification of the original patient source with “95% accuracy.”As one investigative report noted, “The unsettling part was how precisely the patients were flagged in another dataset, with near perfect accuracy…”

GE’s internal investigation caused some consternation in the firms legal wing, but they eventually concluded they had not technically violated HIPAA because the manipulations were one step removed from direct patient data collection. GE’s finance department was much relieved. GE’s health database and proprietary software was sold to New York private equity firm Veritas Capital, (who in the past had also bought and sold Truven) which in turn resold the entire medical records business for $17 billion on the open market.

Channeling their inner Arthur Sackler, IQVIA (formerly Quintiles, formerly IMS) justified their actions, saying they are all about improving patient outcomes by identifying what treatments work best for what diseases. What all now admit behind closed doors is that HIPAA is hopelessly outdated, and that the glaring loopholes have been identified and commercially advantaged. 

In many respects, this is old news. In 1957, when Arthur Sackler appeared under oath before the Kefauver Commission in January, 1962, he lied through his teeth, denying his ownership of IMS. Now 35 years later, his ghost and the IMS progeny continue to haunt our personal health data.

Mike Magee, MD is a Medical Historian and author of  CodeBlue: Inside the Medical Industrial Complex”.

from The Health Care Blog https://ift.tt/nXwuhqr

Will Boeglin demos TimeDoc Health

Will Boeglin is CEO of TimeDoc Health. It’s one of a new breed of companies supplying the capability for physician groups and health systems (including FQHCs) to deliver CCM (chronic care management) and RPM (remote patient monitoring). Both of those services are now reimbursed by Medicare, and some private plans, but rolling them out and tracking all that activity–not to mention accounting and billing for it–is non-trivial for practices. That is where TimeDoc comes in. Will started the company as part of a med-school project and just raised $48m to really get it going. He showed me how it worked, and gave an extensive and interesting demo–Matthew Holt

from The Health Care Blog https://ift.tt/kcPrlvy

Virtual Care Regulatory Round-Up: Telehealth & Digital Care ‘State-of-Play’ by Nathaniel Lacktman

BY JESS DaMASSA, WTF HEALTH

Just as HHS extends the Covid-19 public health emergency waivers until July, we kick-off a brand-new monthly interview series about the state-of-play for all things telehealth and digital care policy and reimbursement. Called the WTF Health Virtual Care Regulatory Round-up, we’re partnering with our friends at Wheel to feature health policy experts, lobbyists, health plan folks, and other virtual care experts and insiders who can keep us updated on the changing regulations and what they will mean to those health tech co’s whose businesses rely on virtual care.

Attorney-to-the-stars-of-telehealth, Nathaniel Lacktman, who chairs the Telemedicine & Digital Health Industry Team at Foley & Lardner and is a Board member of the American Telemedicine Association (ATA), kicks the series off for us with an update on those public health waivers and how he is coaching health tech businesses in preparing for the inevitable transition of care that will come when they come to an end.

What will happen to patients who live across state lines from their virtual care providers? What business decisions need to be made to avoid abandoning patients and maintaining continuity of care? Nate’s not bullish on a federal national license, but there are some cases where cross-state patient-provider relationships can continue to exist – they just might not work for everyone’s business model.

And, on the subject of telehealth business models, Nate gives us his take on where he thinks reimbursement will be headed, how policy around virtual prescribing will be impacted post-pandemic (particularly around controlled substances), and whether or not Medicare’s originating site requirement will be put back in place. We also get Nate’s perspective on which virtual care business models seem to be working best among health tech startups and what legal risk those more ‘reckless’ players might be creating for the rest of the field without even realizing it. Great education on virtual care and what’s happening in the space RIGHT NOW. Watch!

Special thanks to our series sponsor, Wheel – the health tech company powering the virtual care industry. Wheel provides companies with everything they need to launch and scale virtual care services — including the regulatory infrastructure to deliver high quality and compliant care. Learn more at wheel.com.

from The Health Care Blog https://ift.tt/A4QPH7g